Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Phase II/III study to investigate the efficacy of 5-aminolaevulinic acid (ALA)-based photodynamic therapy in the treatment of Bowen's disease, actinic keratoses and study the effect of dose fractionation for superficial basal cell carcinomas
ISRCTN ISRCTN93864182
ClinicalTrials.gov identifier
Public title Phase II/III study to investigate the efficacy of 5-aminolaevulinic acid (ALA)-based photodynamic therapy in the treatment of Bowen's disease, actinic keratoses and study the effect of dose fractionation for superficial basal cell carcinomas
Scientific title
Acronym N/A
Serial number at source N0436118001
Study hypothesis To continue to investigate the efficacy of ALA-based photodynamic therapy in the treatment of Bowen's disease and actinic keratoses. To study the effect of dose fractionation for superficial basal cell carcinomas using a randomised trial.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised active controlled parallel group trial
Countries of recruitment United Kingdom
Disease/condition/study domain Bowen's disease
Participants - inclusion criteria Recruited from clinical oncology consultants to whom patients are referred at a district general hospital. Also direct from consultant dermatologists/plastic surgeons in Leeds and Airedale.
Participants - exclusion criteria Does not match inclusion criteria
Anticipated start date 01/02/2002
Anticipated end date 01/02/2004
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Controlled trial without randomisation; Randomised controlled trial, Random allocation to:
1 Standard photodynamic therapy for superficial basal cell carcinoma
2 Dose fractionated photodynamic therapy
Primary outcome measure(s) Complete remission of skin tumour and future recurrence.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Leeds Teaching Hospitals NHS Trust (UK)
Trial website
Publications
Contact name Dr  F  Roberts
  Address Clinical Oncology
Cookridge Hospital
Hospital Lane
  City/town Leeds
  Zip/Postcode LS16 6QB
  Country United Kingdom
  Tel +44 (0)113 392 4253
  Fax +44 (0)113 392 4214
  Email comdhfo@stjames.leeds.ac.uk
Sponsor Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)207 307 2622
  Fax +44 (0)207 307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.doh.gov.uk
Date applied 12/09/2003
Last edited 12/08/2009
Date ISRCTN assigned 12/09/2003
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central